GSDMA and cancer: We specifically identified somatic mutations that are predicted to disrupt miRNA target sites within genes, including TAL1, SCG3, and GSDMA, that are over-expressed in cancer and mutations that are predicted to create new miRNA target sites within genes, including MITF and EPHA3, that are underexpressed in cancer.